EUCTR2010-019585-90-AT进行中（未招募）不适用
A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Combination with the HCV Polymerase Inhibitor Prodrug RO5024048 and/or Pegasys® in Chronic Hepatitis C Genotype 1 Patients Who Failed with a Previous Course of Peginterferon alfa plus Ribavirin Combination Therapy - Matterhorn
F.Hoffmann-La Roche0 个研究点目标入组 420 人开始时间: 2011年2月24日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Adult patients, age 18 years and older
- •- Presence of hepatitis C infection, genotype 1a or 1b
- •- Documentation of previous treatment failure after receiving approved doses of peginterferon plus ribavirin for at least 12 weeks
- •- Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to study start
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 395
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •- Infection with any hepatitis C genotype or subtype other than genotype 1a or 1b
- •- Patients with cirrhosis
- •- Patients who were discontinued from previous peginterferon plus ribavirin therapy due to reasons other than insufficient therapeutic response
- •- Co-infection with hepatitis B or human immunodeficiency virus (HIV)
- •- History or evidence of chronic liver disease other than hepatitis C
研究者
相似试验
进行中（未招募）
不适用
A research study of a new medicine, danoprevir, with ritonavir and Copegus (also known as ribavirin), in combination with another new medicine, RO5024048, and/or Pegasys for the treatment of a disease called chronic hepatitis C, which causes damage to the liver, in patients that failed a previous treatment for hepatitis C.Chronic Hepatitis CMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-019585-90-DEF.Hoffmann-La Roche381
进行中（未招募）
1 期
A research study of a new medicine, danoprevir, with ritonavir andCopegus (also known as ribavirin), in combination with another newmedicine, RO5024048, and/or Pegasys for the treatment of a diseasecalled chronic hepatitis C, which causes damage to the liver, in patientsthat failed a previous treatment for hepatitis C.Chronic Hepatitis CMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-019585-90-ESF.Hoffmann-La Roche420
进行中（未招募）
不适用
A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCVProtease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus, inCombination with the HCV Polymerase Inhibitor Prodrug RO5024048 and/or Pegasys in ChronicHepatitis C Genotype 1 Patients Who Failed with a Previous Course of Peginterferon alfa plus RibavirinCombination Therapy - MatterhorEUCTR2010-019585-90-ITF.Hoffmann-La Roche420
进行中（未招募）
不适用
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic AsthmaSevere persistent allergic asthmaEUCTR2015-003533-10-Outside-EU/EEAovartis123
进行中（未招募）
1 期
A research study of a new medicine, danoprevir, with ritonavir and Copegus (also known as ribavirin), in combination with another new medicine, RO5024048 and/or Pegasys for the treatment of a disease called chronic hepatitis C, whch causes damge to the liver, in patients that failed a previous treatment for hepatitis C.EUCTR2010-019585-90-GBF.Hoffmann-La Roche420